Celldex CDX527-01 (Solid tumors)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Get the study drug (CDX-527) by IV
- Give tumor tissue
- Have physical exams, blood and urine tests
- Have heart scans (ECG)
- Have radiographs (X-rays)
- Have imaging scans (MRI and or CT)
What is the Condition Being Studied?
Ovarian Cancer

Who Can Participate in this Study?

Adults who are diagnosed with ovarian cancer.

For more information about who can join this study, please contact the study team at CCI-TrialReferrals@duke.edu or 919-681-6468.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out if an experimental drug (CDX-527) is a safe and effective treatment for your cancer.

Study Details

Full Title
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX 527 in Patients with Advanced Malignancies
Principal Investigator

Contacts
Center for Cancer Immunotherapy DCI Clinical Research Team
Protocol Number
IRB:
PRO00105515

NCT:
NCT04440943
ClinicalTrials.gov
View on ClinicalTrials.gov